Actionable Intelligence

Frequency: Monthly
Annual Subscription: $1,999.00 
Single Issue: $299.00

SPECIAL OFFER: Click here to get two issues of The Burrill Biotechnology Report free!

The Burrill Biotechnology Report has the detailed market intelligence you need each month to obtain an accurate overview of all the latest global developments and trends in the life sciences industry.

BBR is published monthly (except for a combined August/September issue). It may be purchased as an annual subscription or as  individual issues.

With your annual subscription you will also receive the following special free reports:

• The Personalized Medicine Report 2008 (November 2008)
• Biotech 2009—the 23rd annual review of the industry
• The Stem Cell Report (March 2009)
• The Aging Report (December 2009 *Publication to be confirmed)

November, 2008:
Piecing Together the Personalized Medicine Puzzle



Features:

• Personalized Medicine Becoming a Reality
• Interview: Carol Kovac Burrill & Company
• Advancing the Personalized Medicine Paradigm
• Industry Focus: Biofuels
• Financial Performance of Publicly Listed Biotech Companies

...and More!

Annual Subscription: $1,999.00 
Single Issue: $299.00

Burrill Biotechnology News: FREE Weekly E-zine
Sign up for BBR’s free weekly e-zine that will bring you details of what is happening in the global world of life sciences business and financing. Just for signing up we will provide you with the George Scangos CEO Interview that appears in the August/September issue of BBR.

 

ARCHIVE

 

October, 2008: Wall Street Goes On A Wild Ride

Features:

• Is The Party Over In India?
  
• Growth of revenues slows, report finds
  
• CNS Disorders—Alzheimer’s disease
• Analysis of market trends
• By The Numbers
  •    Performance of Biotech Indices and Capital Raised
  •    Burrill Canadian Biotech Index
  •    India Index, Q308

CEO Interview: Glenmark Pharmaceuticals—A Model For Success
Tania Fernandez sat down with Glenn Saldanha, Managing Director and CEO of the company to determine how they have been able to achieve rapid growth

 

August/September, 2008: The Perfect Storm

The inaugural 125-page August/September issue features “By the Numbers”—biotech’s global report card for first half of 2008 including:

• Total Financings
• Public Financings by Company
• Public Financings by Therapeutic Area
• Top 20 Venture Financings
• Venture Financings by Therapeutic Area
• Venture Financings by State
• Change in Biotech Market Cap
• Burrill Public Biotech Companies Performance
• Biotech IPOs Performance
• M&A/Partnering
• Country features on Europe, Canada, China & India

CEO Interview: Weathering the Storm
This "in-depth" interview features with George Scangos, CEO of Exelixis, who paints a very sobering picture of today’s turbulent economic climate and its impact on the biotech industry: With investors in risk-avoidance mode and demanding later and later data on lead products before they invest, where will the cash come from to conduct later trials in order to satisfy these demands?